Please find attached Outcome of Board Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Microcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Veerhealth Care's Board approved audited results for FY25. Revenue from operations grew about 26% to Rs. 1,667.05 lakhs (vs Rs. 1,322.31 lakhs in FY24), driven by a strong Q4 where revenue jumped to Rs. 562 lakhs from Rs. 336.72 lakhs a year ago. However, profit before tax fell sharply to Rs. 50.78 lakhs from Rs. 128.14 lakhs, and full-year PAT slipped marginally to Rs. 39.14 lakhs from Rs. 40.60 lakhs. Q4 PAT remained negative at Rs. -9.93 lakhs, though much improved from Rs. -55.37 lakhs in Q4 FY24. The Board skipped dividend to conserve cash, and operating cash flow turned negative at Rs. -39.32 lakhs, with heavy capex of Rs. 880.91 lakhs funded by new long-term borrowings of Rs. 419.90 lakhs. Auditor issued an unmodified opinion.
Revenue growth is positive, but margin compression, negative operating cash flow, and rising debt for capex are red flags. Skipped dividend and weaker bottom line may weigh on the stock despite the top-line improvement.